Mark Sheptoff Financial Planning LLC Decreases Holdings in DexCom, Inc. (NASDAQ:DXCM)

Mark Sheptoff Financial Planning LLC reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 4.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,860 shares of the medical device company’s stock after selling 200 shares during the period. Mark Sheptoff Financial Planning LLC’s holdings in DexCom were worth $551,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in DXCM. Vanguard Group Inc. grew its stake in shares of DexCom by 0.3% in the first quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock valued at $6,186,539,000 after buying an additional 136,282 shares in the last quarter. Capital Research Global Investors grew its position in DexCom by 21.4% in the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock valued at $1,898,085,000 after acquiring an additional 2,695,296 shares in the last quarter. Sands Capital Management LLC raised its stake in shares of DexCom by 10.2% during the fourth quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock valued at $1,868,647,000 after purchasing an additional 1,398,136 shares during the period. Capital World Investors lifted its position in shares of DexCom by 130.7% during the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after purchasing an additional 5,256,092 shares in the last quarter. Finally, Artisan Partners Limited Partnership lifted its position in shares of DexCom by 164.8% during the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock worth $732,169,000 after purchasing an additional 3,672,471 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Stock Performance

Shares of DXCM opened at $69.46 on Thursday. The firm has a fifty day moving average of $79.87 and a 200-day moving average of $110.26. The company has a market cap of $27.62 billion, a price-to-earnings ratio of 44.81, a price-to-earnings-growth ratio of 2.12 and a beta of 1.18. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.39 by $0.04. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. DexCom’s revenue was up 15.3% compared to the same quarter last year. During the same quarter last year, the business earned $0.34 earnings per share. As a group, equities analysts anticipate that DexCom, Inc. will post 1.69 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on DXCM shares. Canaccord Genuity Group reaffirmed a “buy” rating and set a $145.00 price target on shares of DexCom in a research note on Tuesday, July 23rd. Wells Fargo & Company reduced their price target on DexCom from $145.00 to $80.00 and set an “overweight” rating for the company in a report on Friday, July 26th. Oppenheimer dropped their price objective on DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, July 26th. Redburn Atlantic started coverage on DexCom in a research note on Thursday, May 30th. They set a “neutral” rating and a $130.00 target price for the company. Finally, Robert W. Baird lifted their price target on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, August 5th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $112.25.

Insider Buying and Selling at DexCom

In other news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction on Friday, June 28th. The stock was sold at an average price of $114.29, for a total value of $75,317.11. Following the completion of the transaction, the executive vice president now owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Michael Jon Brown sold 659 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $114.29, for a total value of $75,317.11. Following the completion of the sale, the executive vice president now owns 66,901 shares of the company’s stock, valued at $7,646,115.29. The disclosure for this sale can be found here. Insiders have sold 2,483 shares of company stock valued at $201,708 in the last quarter. Corporate insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.